Robotic Surgery, Mastectomy and Cancer: What the US FDA's Safety Communications Really Say

In a safety communication first issued on 28 February 2019 and updated on 20 August 2021, the US Food and Drug Administration said that the safety and effectiveness of robotically-assisted surgical devices in mastectomy, or in preventing or treating cancer, has not been established. FDA's current overview page adds that it has not granted marketing authorisation for any such device specifically for the prevention or treatment of cancer. This article sets out what those US documents say, using the texts in our FDA surgical robotics and SaMD base. It describes the US regulator's position only. It does not cover the MHRA, the NHS or UKCA/CE marking, and it is not medical advice.

A US statement, read from the UK

British readers come to this subject from two directions: people researching a treatment option they have read about, and UK medtech teams whose robots are sold, or will be sold, in the US. For both, the main caution is the same. These documents describe what FDA has and has not authorised for the US market. The base contains no UK or European material, so it cannot tell you what the MHRA or any UK body has said on robotic mastectomy. Please check UK official sources for that.

The exact words

• “The safety and effectiveness of using robotically-assisted surgical devices in mastectomy procedures or in the prevention or treatment of cancer has not been established.”
• “There is limited, preliminary evidence that the use of robotically-assisted surgical devices for treatment or prevention of cancers that primarily (breast) or exclusively (cervical) affect women may be associated with diminished long-term survival.”
• “To date, the FDA has not granted marketing authorization for any robotically-assisted surgical device for use in the United States for the prevention or treatment of cancer, including breast cancer.”
• The FDA “has not granted any RAS device marketing authorization for mastectomy.”

FDA balances these warnings. Its overview page says robotically-assisted surgery “is safe and effective for performing certain procedures when used appropriately and with proper training”, and lists cleared laparoscopic uses in general, cardiac, colorectal, gynaecological, head and neck, thoracic and urological surgery. The caution applies to mastectomy and to cancer outcomes, not to robotic surgery as a whole.

Why: 30-day evidence versus long-term cancer outcomes

FDA explains that its evaluation of these devices “has generally focused on determining whether the complication rate at 30 days is clinically comparable to other surgical techniques”. Clearances for procedures often performed in people with cancer, such as hysterectomy, prostatectomy and colectomy, rest on 30-day follow-up. Supporting a cancer indication would require outcomes such as local recurrence, disease-free survival or overall survival over “time periods much longer than 30 days”.

On cervical cancer, FDA refers to a limited report (New England Journal of Medicine, November 2018) in which minimally invasive radical hysterectomy, laparoscopic or robotic, appeared to be associated with lower long-term survival than open surgery. It notes that other researchers found no statistically significant difference. FDA presents this as information to be aware of, not as a conclusion.

FDA's own audience list is broad. It names people with breast cancer or at high risk who are considering mastectomy, people considering robotic surgery for other cancers, and clinicians across specialties from breast and gynaecological surgery to urology, colorectal surgery and oncology nursing.

What FDA recommends

For patients, FDA suggests asking the surgeon about their training, experience and outcomes with robotic procedures, how many procedures like theirs they have carried out, and about possible complications and their frequency. For clinicians, FDA recommends training for the specific procedures performed and honest discussion of experience and expected outcomes. It also reminds clinicians that no robotic system has been cleared or approved on the basis of cancer-related outcomes. FDA's adverse event route for these concerns is its MedWatch programme, a US system.

• FDA says it does not supervise or accredit physician training; training is a matter for manufacturers, physicians and health care facilities.
• Different robot models may operate differently, so FDA advises training on each model.
• FDA encourages patient registries for all uses of these devices, to help study learning curves and long-term outcomes.
• Studies of unapproved uses such as cancer treatment, even on registry infrastructure, must be conducted under an Investigational Device Exemption in the US.

Points that are often misreported

Coverage of this communication sometimes goes further than FDA did. Measured against the text itself, four claims come up repeatedly:

1. “The FDA has banned robotic mastectomy.” There is no ban in these documents. FDA notes that it regulates devices and generally does not regulate the practice of medicine between a clinician and a patient. What it states is that no device is authorised for mastectomy and that safety and effectiveness have not been established.
2. “A robot cleared for hysterectomy is cleared for cervical cancer.” A procedure clearance based on 30-day follow-up is not an authorisation to prevent or treat cancer.
3. “The evidence shows robotic surgery shortens survival.” FDA describes the evidence as limited and preliminary, and cites conflicting findings on long-term survival after cervical cancer surgery.
4. “An adverse event report proves the robot was faulty.” FDA warns that reports can be incomplete, inaccurate or unverified, and that a report does not necessarily indicate a defective device.

Reading the primary text avoids each of these errors. That matters for journalists, patient groups and, above all, for companies whose sales teams may repeat second-hand summaries to US hospitals.

Implications for UK companies selling robots in the US

For a British manufacturer, the practical message concerns claims. US clearance for a procedure is not authorisation to treat the disease behind it. FDA's draft RASD premarket guidance, issued on 25 September 2026 and not yet final, recommends a labelling statement that outcomes related to treating the underlying disease or condition were not evaluated. It also says the umbrella and covered procedure approach is not suitable for seeking authorisation to treat a specific disease or condition.

1. Audit US-facing marketing, training slides and conference material for implied mastectomy or cancer-outcome claims.
2. Keep US and non-US messaging consistent with each market's own rules. The base only covers the US side.
3. If you aim for a cancer-related US indication, plan for long-term oncological endpoints and an IDE.
4. Route US field reports into your Part 803 Medical Device Reporting process. FDA notes that most reports on these devices concern malfunctions, but it has also received reports of injuries and deaths.

To check a precise point, ask the base, for example “Is it safe to use a surgical robot for a mastectomy?” The answer reports FDA's wording and makes clear that it is not individual advice.

Sources: FDA, Computer-Assisted Surgical Systems and the 2021 update of FDA's safety communication (archived copy). FDA says it will update the communication if significant new information emerges.